newcleo is an advanced nuclear technology company going public through a merger with NewHold Investment Corp. III (NASDAQ: NHIC). The deal was approved on September 17, 2026 and the combined company began trading on September 22, 2026 under NWCL. The setup offers a large PIPE and a big clean-energy story, but investors should watch dilution, licensing risk, and how much trust cash actually made it through closing.
newcleo is an advanced nuclear technology company going public through a merger with NewHold Investment Corp. III (NASDAQ: NHIC). The deal was approved on September 17, 2026 and the combined company began trading on September 22, 2026 under NWCL. The setup offers a large PIPE and a big clean-energy story, but investors should watch dilution, licensing risk, and how much trust cash actually made it through closing.
newcleo was founded in 2021 by Stefano Buono and is building advanced modular reactors, specifically lead-cooled fast reactors, along with the fuel-cycle infrastructure needed to support them. The company’s pitch is vertically integrated: it is developing reactor technology, mixed-oxide fuel made from recycled nuclear materials, and related supply-chain capabilities aimed at improving nuclear cost, safety, and waste performance. In the deal materials, newcleo says it is headquartered in London and has more than 900 employees across Europe and the U.S., plus 100+ industry partnerships.
The company is positioning itself as part of the advanced nuclear and clean baseload power theme, with demand tied to industrial users, energy security, decarbonization, and electricity demand from AI infrastructure. Its investor materials reference licensing and deployment efforts in France, Slovakia, the U.S., and Italy, with regulatory engagement underway with the NRC and French authorities. That puts newcleo in a category that is still early, capital-intensive, and highly dependent on permitting and execution rather than near-term commercial scale.
The SPAC Deal
newcleo agreed to merge with NewHold Investment Corp. III, which trades today under the ticker NHIC. The May 2026 investor presentation says the transaction implies a pre-transaction newcleo equity value of about $2.4 billion, with a pro forma enterprise value of $2.374 billion and a pro forma market capitalization of $2.903 billion at a $10.00 share price assumption. That valuation matters because this is still an early-stage nuclear platform, so investors are effectively paying for development progress, licensing optionality, and future commercialization rather than a mature earnings stream.
On financing, NewHold disclosed $212.934 million in trust as of June 30, 2026, and the materials say the deal could provide up to $209 million from trust before redemptions and transaction expenses. The transaction also includes a $220 million PIPE for 22,000,000 newcleo ordinary shares at $10.00 per share, before about $9.6 million of PIPE transaction costs. The company said the deal could provide up to $429 million in gross proceeds when combining PIPE and trust cash. NewHold shareholders approved the merger on September 17, 2026, closing was expected on or about September 21, 2026, and newcleo later said the business combination closed with trading on Nasdaq under NWCL beginning September 22, 2026. The combined company’s warrants are expected to trade as NWCLW.
Dilution is a major part of the setup. The investor presentation says 20% of the sponsor promote is forfeited upfront, with the rest subject to forfeiture based on delivered capital and price vesting. The same materials show expected pro forma ownership of 84.4% for newcleo investors, 7.6% for NewHold public shareholders, 7.0% for NewHold founders, and 1.1% for PIPE investors. The filing also lists a sizable overhang from continuing options, RSUs, warrants, newcleo public and private warrants, earnouts, and unvested sponsor promote, which means the headline valuation does not translate cleanly into per-share economics.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The SPAC route gives newcleo a faster path to public capital than a traditional IPO and allows it to pair the listing with committed financing. That matters for a capital-intensive business like advanced nuclear, where the company needs funding for reactor development, fuel-cycle buildout, and regulatory work across multiple jurisdictions.
The deal also lets newcleo market a long-duration growth story to public investors while pointing to its private funding history and operating progress. In the materials, the company says it had more than $80 million in revenue, other income, and financial income in 2024 and about $780 million in private funding, which helps frame the business as beyond pure concept stage even though commercialization is still ahead.
Financial Highlights
newcleo’s first-half 2026 results show early operating traction but still heavy losses. The company reported €19.4 million of revenue from products and services in H1 2026, up 46% year over year, alongside a net loss of €82.0 million. It also reported €25.3 million of capital expenditures in the period, which underscores how capital-intensive the buildout remains.
Liquidity is still a key watch item. newcleo reported €66.5 million of cash and cash equivalents at June 30, 2026, then said it had preliminary unaudited cash and cash equivalents of €233 million as of September 30, 2026. The sources reviewed here do not provide a full audited 2025 income statement or a detailed forward revenue/EBITDA table, so any longer-term growth view should be treated as management’s projection rather than established operating history.
Risk Factors
The biggest risk is execution. newcleo is trying to commercialize advanced modular reactors and build fuel-cycle infrastructure at the same time, which means technical development, manufacturing scale-up, and project delivery all have to line up. On top of that, the company faces regulatory and licensing risk in the U.S. and Europe, including engagement with the NRC and French authorities, and those approvals can take time.
De-SPAC-specific risks are just as important. Redemption risk can shrink the cash that actually comes out of trust, even though the deal had non-redemption agreements in place. Dilution is also meaningful from the sponsor promote, PIPE, warrants, options, RSUs, earnouts, and other securities. Investors should also watch cash runway, because this is a capital-intensive business and the trust plus PIPE only bridge part of the funding need. If commercialization slips, the equity story can re-rate quickly.
Comparable Public Companies
The company itself points to Oklo (OKLO), NuScale Power (SMR), and X-energy as peer references. Of those, OKLO and SMR are public comps, while X-energy is private. A broader public comparison set can also include GE Vernova (GEV) for nuclear and power-infrastructure exposure, though it is not a pure-play advanced reactor company.
I did not pull live trading multiples here, so I can’t responsibly quote current valuation ranges. The right way to think about the comp set is that public advanced-nuclear names tend to trade on long-duration optionality, policy support, and execution milestones rather than current earnings. That means sentiment can move sharply on licensing updates, financing news, and commercialization timing.
For cross-linking, the comparable tickers are OKLO, SMR, and GEV.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
The bottom line is that newcleo is one of the more interesting de-SPACs in the advanced nuclear space because it combines reactor development, fuel-cycle infrastructure, and a large financing package. The setup matters now because this is not a conventional energy IPO; it is a bet on a vertically integrated nuclear platform with real regulatory and capital needs, and the public-market listing gives investors a cleaner way to track progress from here.
Shareholders should watch three things: how much trust cash ultimately survived redemptions, whether the PIPE closes as expected, and whether newcleo can keep advancing licensing and commercialization without burning through capital too quickly. With NHIC now converted into NWCL, the story shifts from deal mechanics to execution, and that is where the equity will be judged.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Picture
Want the full picture on NWCL?
Everything we track on NWCL in one place — the TickerSpark Score, price charts, key financials, and our latest coverage.